Search
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … [L41524] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.
Mixtures: ZEPOSIA 7-Day Starter Pack, ZEPOSIA 7-Day Starter PackCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedThe barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. … A gel made of bovine collagen is used as the matrix for cell growth and differentiation.
Aluminum oxide
go.drugbank.com/drugs/DB11342ApprovedWithdrawnIt is considered an indirect additive used in food contact substances by the FDA. … Aluminum oxide has a chemical formula Al2O3. It is amphoteric in nature, and is used in various chemical, industrial and commercial applications.
Mixtures: POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOSProducts: ALUMINIUM HYDROXIDE MIXTURE BP 4% w/w, ALUTACID ANTACID MIXTURE 4% w/wVaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalThough it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. … It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: VERLIN TABLETAS X 50 MG, VOXAMIN® TABLETA RECUBIERTAPlecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC). … It should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Categories: Guanylate Cyclase-C Agonist, Guanylyl Cyclase C AgonistsVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigational[A253702] Furthermore, vonoprazan is 350-times more potent than the proton-pump inhibitor [lansoprazole], thanks to its ability to accumulate in the gastric corpus mucosa, specifically in the parietal … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamineIsatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalFollowing three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Products: SARCLİSA 100 MG/5 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, SARCLİSA 500 MG/25 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETBivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalOnce bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Products: BIVACARD 250 MG IV ENJEKSIYON VE INFÜZYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON, 1 ADET, ANGIOMAX® POLVO LIOFILIZADO PARA RECONSTRUIR A SOLUCIÓN INYECTABLE (50MG/ML)Trimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigational[L33015] Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s. … Trimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride